Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06842355 · ClinicalTrials.gov registry record · Phase 2
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
A Phase 2 study of Achondroplasia, sponsored by Tyra Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 13
- Study locations
NCT06842355: Recruiting Phase 2 study of Achondroplasia, sponsored by Tyra Biosciences.
NCT06842355 is a Phase 2 study of Achondroplasia that is actively recruiting participants, run by Tyra Biosciences. The registered enrollment target is 92 participants, below the 141-participant average among 9 other Achondroplasia trials with a reported enrollment target (35% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06842355, a Phase 2 study of Achondroplasia, is actively recruiting participants, sponsored by Tyra Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
Conditions Studied
Interventions
- DRUG TYRA-300 0.125 mg/kg
- DRUG TYRA-300 0.25 mg/kg
- DRUG TYRA-300 0.375 mg/kg
- DRUG TYRA-300 0.50 mg/kg
Study Locations (13)
Maryland
- Johns Hopkins University School of Medicine - Baltimore
- Uncommon Cures - Chevy Chase
Missouri
- University of Missouri - Columbia
- Washington University - St Louis
California
- Lundquist Institute for Biomedical Innovation - Torrance
Colorado
- Children's Hospital Colorado - Aurora
Delaware
- Nemours Alfred I duPont Hospital for Children - Wilmington
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Children's Medical Center, Dallas - Dallas
Wisconsin
- University of Wisconsin-Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2025-03-04 |
| Est. Completion | 2030-06 |
| Phase | Phase 2 |
What NCT06842355 shows while recruiting
NCT06842355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 141-participant average among 9 other Achondroplasia trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 4 interventions - of which TYRA-300 0.125 mg/kg is the first listed.
NCT06842355 lists 13 locations in 11 states (Maryland, Missouri, California).
Frequently Asked Questions
What is clinical trial NCT06842355 about?
NCT06842355 is a clinical study titled "A Study of TYRA-300 in Children With Achondroplasia: BEACH301". The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
What is the current status of trial NCT06842355?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2025-03-04. Estimated completion is 2030-06.
What conditions does trial NCT06842355 study?
This clinical trial studies the following conditions: Achondroplasia.
What interventions are being tested in trial NCT06842355?
The interventions under investigation include: TYRA-300 0.125 mg/kg (DRUG), TYRA-300 0.25 mg/kg (DRUG), TYRA-300 0.375 mg/kg (DRUG), TYRA-300 0.50 mg/kg (DRUG).
Who is sponsoring clinical trial NCT06842355?
This trial is sponsored by Tyra Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06842355 being conducted?
This trial has 13 study locations across California, Colorado, Delaware, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06842355's enrollment target sits among peer trials
92 5th of 9 higher than 5 of 9 other Achondroplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Achondroplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
RECRUITING · Phase 2
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING · Phase 2
-
VIrtual STudy in Achondroplasia for the US (VISTA)
RECRUITING
-
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI